Literature DB >> 17720243

Analysis of gene expression profile of TPM3-ALK positive anaplastic large cell lymphoma reveals overlapping and unique patterns with that of NPM-ALK positive anaplastic large cell lymphoma.

Sandra D Bohling1, Stephen D Jenson, David K Crockett, Jonathan A Schumacher, Kojo S J Elenitoba-Johnson, Megan S Lim.   

Abstract

Anaplastic large cell lymphoma (ALCL) comprises a group of non-Hodgkin lymphomas characterized by the expression of the CD30/Ki-1 antigen. A subset of ALCL is characterized by chromosomal translocations involving the anaplastic lymphoma kinase (ALK) gene on chromosome 2. While the most common translocation is the t(2;5)(p23;q35) involving the nucleophosmin (NPM) gene on chromosome 5, up to 12 other translocations partners of the ALK gene have been identified. One of these is the t(1;2)(q25;p23) which results in the formation of the chimeric protein TPM3-ALK. While several of the signaling pathways induced by NPM-ALK have been elucidated, those involved in ALCLs harboring TPM3-ALK are largely unknown. In order to investigate the expression profiles of ALCLs carrying the NPM-ALK and TPM3-ALK fusions, we carried out cDNA microarray analysis of two ALCL tissue samples, one expressing the NPM-ALK fusion protein and the other the TPM3-ALK fusion protein. RNA was extracted from snap-frozen tissues, labeled with fluorescent dyes and analyzed using cDNAs microarray containing approximately 9,200 genes and expressed sequence tags (ESTs). Quantitative fluorescence RT-PCR was performed to validate the cDNA microarray data on nine selected gene targets. Our results show a significant overlap of genes deregulated in the NPM-ALK and TPM-ALK positive lymphomas. These deregulated genes are involved in diverse cellular functions, such as cell cycle regulation, apoptosis, proliferation, and adhesion. Interestingly, a subset of the genes was distinct in their expression pattern in the two types of lymphomas. More importantly, many genes that were not previously associated with ALK positive lymphomas were identified. Our results demonstrate the overlapping and unique transcriptional patterns associated with the NPM-ALK and TPM3-ALK fusions in ALCL.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17720243     DOI: 10.1016/j.leukres.2007.07.012

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  4 in total

1.  Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy.

Authors:  Brunangelo Falini; Maria Paola Martelli
Journal:  Haematologica       Date:  2009-07       Impact factor: 9.941

Review 2.  Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.

Authors:  Thomas R Webb; Jake Slavish; Rani E George; A Thomas Look; Liquan Xue; Qin Jiang; Xiaoli Cui; Walter B Rentrop; Stephan W Morris
Journal:  Expert Rev Anticancer Ther       Date:  2009-03       Impact factor: 4.512

3.  NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.

Authors:  Joel D Pearson; Jason K H Lee; Julinor T C Bacani; Raymond Lai; Robert J Ingham
Journal:  J Signal Transduct       Date:  2012-07-18

4.  A comparative global phosphoproteomics analysis of obinutuzumab (GA101) versus rituximab (RTX) against RTX sensitive and resistant Burkitt lymphoma (BL) demonstrates differential phosphorylation of signaling pathway proteins after treatment.

Authors:  Aradhana Awasthi; Delphine C M Rolland; Janet Ayello; Carmella van de Ven; Venkatesha Basrur; Kevin Conlon; Damian Fermin; Matthew J Barth; Christian Klein; Kojo S J Elenitoba-Johnson; Megan S Lim; Mitchell S Cairo
Journal:  Oncotarget       Date:  2017-12-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.